Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Nat Cancer. 2021 Jan 11;2(2):189–200. doi: 10.1038/s43018-020-00160-x

Fig. 6: Glutaminase inhibition in combination with immune checkpoint blockade suppresses the growth of Arid1a/Pik3ca OCCC.

Fig. 6:

a, Glutamine levels in the OCCCs developed from the Arid1a/Pik3ca genetic mouse model treated with vehicle control or CB-839 (n=6 mice/group). b-c, Mice bearing Arid1a/Pik3ca OCCCs were randomized into four indicated treatment groups. Shown are images of reproductive tracts with tumors from the indicated groups at the end of treatment (b). Tumor weight was measured as surrogate for tumor burden (c) (n=6 mice/group). d, After completing treatment, the mice were followed for survival, and the Kaplan-Meier survival curves for each of the indicated groups are shown (n=7 mice/group). e, At end of treatment, percentage of PD1 positive CD8 T cells was assessed by flow cytometry in the peritoneal wash in which tumors have disseminated. Error bars represent mean with s.d. in a and c, and with s.e.m. in e. P values were calculated using two-tailed Student t-test in a, c, e and log-rank test in d.